298 related articles for article (PubMed ID: 28159681)
21. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
[TBL] [Abstract][Full Text] [Related]
22. Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells.
Martelli AM; Lonetti A; Buontempo F; Ricci F; Tazzari PL; Evangelisti C; Bressanin D; Cappellini A; Orsini E; Chiarini F
Adv Biol Regul; 2014 Sep; 56():6-21. PubMed ID: 24819383
[TBL] [Abstract][Full Text] [Related]
23. PKI-587 enhances radiosensitization of hepatocellular carcinoma by inhibiting the PI3K/AKT/mTOR pathways and DNA damage repair.
Xie Y; Liu C; Zhang Y; Li A; Sun C; Li R; Xing Y; Shi M; Wang Q
PLoS One; 2021; 16(10):e0258817. PubMed ID: 34665844
[TBL] [Abstract][Full Text] [Related]
24. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
Brünner-Kubath C; Shabbir W; Saferding V; Wagner R; Singer CF; Valent P; Berger W; Marian B; Zielinski CC; Grusch M; Grunt TW
Breast Cancer Res Treat; 2011 Sep; 129(2):387-400. PubMed ID: 21046231
[TBL] [Abstract][Full Text] [Related]
25. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
26. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.
Schult C; Dahlhaus M; Glass A; Fischer K; Lange S; Freund M; Junghanss C
Anticancer Res; 2012 Feb; 32(2):463-74. PubMed ID: 22287733
[TBL] [Abstract][Full Text] [Related]
27. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
[TBL] [Abstract][Full Text] [Related]
28. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.
Shepherd C; Banerjee L; Cheung CW; Mansour MR; Jenkinson S; Gale RE; Khwaja A
Leukemia; 2013 Mar; 27(3):650-60. PubMed ID: 23038273
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease.
Freitag H; Christen F; Lewens F; Grass I; Briest F; Iwaszkiewicz S; Siegmund B; Grabowski P
Neuroendocrinology; 2017; 105(1):90-104. PubMed ID: 27513674
[TBL] [Abstract][Full Text] [Related]
30. Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.
Leiker AJ; DeGraff W; Choudhuri R; Sowers AL; Thetford A; Cook JA; Van Waes C; Mitchell JB
Clin Cancer Res; 2015 Jun; 21(12):2792-801. PubMed ID: 25724523
[TBL] [Abstract][Full Text] [Related]
31. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.
D'Amato V; Rosa R; D'Amato C; Formisano L; Marciano R; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fusciello C; Veneziani BM; De Placido S; Bianco R
Br J Cancer; 2014 Jun; 110(12):2887-95. PubMed ID: 24823695
[TBL] [Abstract][Full Text] [Related]
32. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
[TBL] [Abstract][Full Text] [Related]
33. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
Bradford LS; Rauh-Hain A; Clark RM; Groeneweg JW; Zhang L; Borger D; Zukerberg LR; Growdon WB; Foster R; Rueda BR
Gynecol Oncol; 2014 May; 133(2):346-52. PubMed ID: 24561032
[TBL] [Abstract][Full Text] [Related]
34. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
35. Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.
Bressanin D; Evangelisti C; Ricci F; Tabellini G; Chiarini F; Tazzari PL; Melchionda F; Buontempo F; Pagliaro P; Pession A; McCubrey JA; Martelli AM
Oncotarget; 2012 Aug; 3(8):811-23. PubMed ID: 22885370
[TBL] [Abstract][Full Text] [Related]
36. Evidence of the immunomodulatory role of dual PI3K/mTOR inhibitors in transplantation: an experimental study in mice.
Vilchez V; Turcios L; Butterfield DA; Mitov MI; Coquillard CL; Brandon JA; Cornea V; Gedaly R; Marti F
Transpl Int; 2017 Oct; 30(10):1061-1074. PubMed ID: 28543637
[TBL] [Abstract][Full Text] [Related]
37. Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with calcineurin inhibition to promote T-ALL cell death.
Tosello V; Saccomani V; Yu J; Bordin F; Amadori A; Piovan E
Oncotarget; 2016 Jul; 7(29):45715-45729. PubMed ID: 27304189
[TBL] [Abstract][Full Text] [Related]
38. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
39. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.
Simioni C; Ultimo S; Martelli AM; Zauli G; Milani D; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2016 Nov; 7(48):79842-79853. PubMed ID: 27821800
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
